Design of novel disturbing peptides against ACE2 SARS-CoV-2 spike-binding region by computational approaches

被引:6
|
作者
Zareei, Sara [1 ]
Pourmand, Saeed [2 ]
Amanlou, Massoud [3 ,4 ]
机构
[1] Kharazmi Univ, Fac Biol Sci, Dept Cell & Mol Biol, Tehran, Iran
[2] Univ Tabriz, Fac Chem & Petr Engn, Dept Chem Engn, Tabriz, Iran
[3] Univ Tehran Med Sci, Fac Pharm, Dept Med Chem, Tehran, Iran
[4] Univ Tehran Med Sci, Expt Med Res Ctr, Tehran, Iran
关键词
SARS-CoV-2; COVID-19; angiotensin converting enyzme 2; peptide design; molecular dynamics simulation; drug discovery; ANGIOTENSIN-CONVERTING ENZYME; RECEPTOR-BINDING; PROTEIN; CORONAVIRUS; ENTRY; EXPRESSION; MUTATIONS; GROMACS; SITE;
D O I
10.3389/fphar.2022.996005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The SARS-CoV-2, the virus which is responsible for COVID-19 disease, employs its spike protein to recognize its receptor, angiotensin-converting enzyme 2 (ACE2), and subsequently enters the host cell. In this process, the receptor-binding domain (RBD) of the spike has an interface with the alpha 1-helix of the peptidase domain (PD) of ACE2. This study focuses on the disruption of the protein-protein interaction (PPI) of RBD-ACE2. Among the residues in the template (which was extracted from the ACE2), those with unfavorable energies were selected for substitution by mutagenesis. As a result, a library of 140 peptide candidates was constructed and the binding affinity of each candidate was evaluated by molecular docking and molecular dynamics simulations against the alpha 1-helix of ACE2. Finally, the most potent peptides P23 (GFNNYFPHQSYGFMPTNGVGY), P28 (GFNQYFPHQSYGFPPTNGVGY), and P31 (GFNRYFPHQSYGFCPTNGVGY) were selected and their dynamic behaviors were studied. The results showed peptide inhibitors increased the radius, surface accessible area, and overall mobility of residues of the protein. However, no significant alteration was seen in the key residues in the active site. Meanwhile, they can be proposed as promising agents against COVID-19 by suppressing the viral attachment and curbing the infection at its early stage. The designed peptides showed potency against beta, gamma, delta, and omicron variants of SARS-CoV-2.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] ACE2 in the Era of SARS-CoV-2: Controversies and Novel Perspectives
    Saponaro, Federica
    Rutigliano, Grazia
    Sestito, Simona
    Bandini, Lavinia
    Storti, Barbara
    Bizzarri, Ranieri
    Zucchi, Riccardo
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [32] Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
    Gurung, Arun Bahadur
    Ali, Mohammad Ajmal
    Lee, Joongku
    Abul Farah, Mohammad
    Al-Anazi, Khalid Mashay
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2021, 14 (02) : 227 - 237
  • [33] Coevolutionary forces shaping the fitness of SARS-CoV-2 spike glycoprotein against human receptor ACE2
    Priya, Prerna
    Shanker, Asheesh
    INFECTION GENETICS AND EVOLUTION, 2021, 87
  • [34] Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein
    Hussain, Mushtaq
    Jabeen, Nusrat
    Raza, Fozia
    Shabbir, Sanya
    Baig, Ayesha A.
    Amanullah, Anusha
    Aziz, Basma
    JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (09) : 1580 - 1586
  • [35] Mapping of ACE2 binding site on SARS-CoV-2 spike protein S1: docking study with peptides
    Kuznetsov, Aleksei
    Jarv, Jaak
    PROCEEDINGS OF THE ESTONIAN ACADEMY OF SCIENCES, 2020, 69 (03) : 228 - 234
  • [36] A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor
    Rajpoot, Sajjan
    Ohishi, Tomokazu
    Kumar, Ashutosh
    Pan, Qiuwei
    Banerjee, Sreeparna
    Zhang, Kam Y. J.
    Baig, Mirza S.
    DRUGS IN R&D, 2021, 21 (03) : 273 - 283
  • [37] Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets
    Shanmugarajan, Dhivya
    Prabitha, P.
    Kumar, B. R. Prashantha
    Suresh, B.
    RSC ADVANCES, 2020, 10 (52) : 31385 - 31399
  • [38] The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies
    Papageorgiou, Anastassios C.
    Mohsin, Imran
    CELLS, 2020, 9 (11) : 1 - 16
  • [39] ACE2: the molecular doorway to SARS-CoV-2
    Miriam Marlene Medina-Enríquez
    Sandra Lopez-León
    José Alberto Carlos-Escalante
    Zuleika Aponte-Torres
    Angelica Cuapio
    Talia Wegman-Ostrosky
    Cell & Bioscience, 10
  • [40] Updated Approaches against SARS-CoV-2
    Li, Haiou
    Zhou, Yunjiao
    Zhang, Meng
    Wang, Haizhou
    Zhao, Qiu
    Liu, Jing
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (06) : 1 - 7